Preparing Your Company for Hatch-Waxman


The Hatch-Waxman Act regulates the relationship between branded and generic drugmakers and attempts to strike a balance between two competing policy interests — encouraging pioneering drug development and facilitating market entry of low-cost, generic alternatives. While most companies go to great lengths to minimize litigation risk, the development of a hit pharmaceutical product all but assures generic competition and ensuing patent disputes. Pharmaceutical companies should therefore incorporate Hatch-Waxman considerations early in their patent prosecution and litigation strategies to set themselves up for future success.

On May 22, please join Principals Caleb Bates and Louis Fogel for a discussion of how pharmaceutical companies can prepare themselves for Hatch-Waxman. Our hosts will discuss the following topics and more:

  • Patent prosecution tips
  • Claim drafting considerations
  • Company policies, procedures, and training
  • Discovery considerations and best practices
  • Identifying and retaining expert witnesses

If you have any questions, please contact [email protected].